^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Non-Hodgkin’s Lymphoma
    Drug:Adcetris (brentuximab vedotin) (Microtubule inhibitor, CD30-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    Scottish Medicines Consortium
    Title:

    brentuximab vedotin (Adcetris®) is accepted for use within NHSScotland

    Published date:
    12/04/2020
    Excerpt:
    brentuximab vedotin (Adcetris®) is accepted for use within NHSScotland...Indication under review: in combination with cyclophosphamide, doxorubicin and prednisone (CHP) for adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL).
    Secondary therapy:
    doxorubicin hydrochloride + cyclophosphamide + prednisone
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    European Medicines Agency
    Published date:
    10/25/2012
    Excerpt:
    Adcetris in combination with cyclophosphamide, doxorubicin and prednisone (CHP) is indicated for adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL).
    Secondary therapy:
    doxorubicin hydrochloride + cyclophosphamide + prednisone
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    European Medicines Agency
    Published date:
    10/25/2012
    Excerpt:
    Adcetris is indicated for the treatment of adult patients with relapsed or refractory sALCL.
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    FDA
    Excerpt:
    ADCETRIS is a CD30-directed antibody-drug conjugate indicated for treatment of adult patients with… Previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with cyclophosphamide, doxorubicin, and prednisone.
    Secondary therapy:
    doxorubicin hydrochloride + cyclophosphamide + prednisone
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    FDA
    Excerpt:
    ADCETRIS is a CD30-directed antibody-drug conjugate indicated for treatment of adult patients with… Systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen.